Maximizing synergies between enabling, and engaging the immune system
Many existing cancer immunotherapy treatments, including current T cell engagers, carry significant safety risks such as cytokine release syndrome. The T-cube platform at the heart of AP Biosciences’ clinical development program addresses this need by enabling conditional T cell activation specifically within the tumor microenvironment through CD137 engagement. This approach not only enhances T cell proliferation and anti-tumor activity but also minimizes systemic toxicity. Additionally, the integration of T-cube’s bispecific antibodies with existing therapies, such as ADCs, can further improve their therapeutic efficacy and safety profile.
T-cube's unique value proposition lies in its conditional T cell activation mechanism
T-cube's unique value proposition lies in its conditional T cell activation mechanism. This platform ensures that T cells are only activated when the bispecific antibody binds to both the tumor-associated antigen and CD137, significantly reducing the risk of cytokine release syndrome. Additionally, it offers modularity of target binding sites for rapid target replacement and superior productivity and yield.
T cells activate only when the bispecific antibody binds both the tumor and CD137
Features
- Modularity of target binding sites, offering rapidly replacement
- Superior productivity and yield
- Bivalent binding activity for each target.
- Balancing efficacy and safety.
